The first- and second-generation antipsychotic drugs affect ADP-induced platelet aggregation

World Journal of Biological Psychiatry

Volumn 11, Issue 2 PART 2, 2010, Pages 268-275

  Dietrich Muszalska, Anna ^a   Rabe Jablonska, Jolanta ^a   Nowak, Pawel ^b   Kontek, Bogdan ^b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF LODZ   (Poland)

Author keywords

Antipsychotics; Clozapine; Olanzapine; Platelet aggregation; Schizophrenia

Indexed keywords

ADENOSINE DIPHOSPHATE; CITRATE SODIUM; CLOZAPINE; HALOPERIDOL; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; MALE; NORMAL HUMAN; ROOM TEMPERATURE; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA;

ADENOSINE DIPHOSPHATE; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; FEMALE; HALOPERIDOL; HUMANS; MALE; PLATELET ACTIVATION; PLATELET AGGREGATION; RISPERIDONE;

EID: 77950795874     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622970802505792     Document Type: Article

References (56)

1. Allebeck P. 1989. Schizophrenia: A life-shortening illness. Schizophr Bull 15:81-89.
2. Abrams CS, Brass LF. 2001. Platelet signal transduction. In: Colman RW, et al. Hemostasis and thrombosis, basic principles and clinical practice. Chapter 31. Philadelphia, PA: Lippincott Williams and Wilkins. p 541-559.
3. Bakken AM, Staeffler A, Jorgensen HA, Holmsen H. 2006. Glycerophospholipid molecular species in platelets and brain tissues-are platelets a good model for neurons? Platelets 17:484-492. (Pubitemid 44665572)
4. Born GVR. 1962. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194:927-929.
5. Brown S. 1997. Excess mortality of schizophrenia: meta-analysis. Br J Psychiatry 171:502-508.
6. Brydon L, Magid K, Steptoe A. 2006. Platelets, coronary heart disease, and stress. Brain Behav Immun 20:113-119. (Pubitemid 43202075)
7. Cadet JL, Lohr J.B. 1989. Possible involvement of free radicals in neuroleptic-induced movement disorders. Evidence from treatment of tardive dyskinesia with vitamin E. Ann NY Acad Sci 570:176-185.
8. De Clerk F. 1990. The role of serotonin in thrombogenesis. Clin Physiol Biochem 8(Suppl 3):40-49.
9. De Clerck F, Somers Y, Mannaert E, Greenspan A, Eerdekens M. 2004. In vitro effects of risperidone and 9-hydroxyrisperidone on human platelet function, plasma coagulation, and fibrynolysis. Clin Ther 26:1261-1273. (Pubitemid 39445348)
10. Dietrich-Muszalska A. 2004. Evaluation of the effects of different concentrations of risperidone, corresponding to the drug doses used in treatment of schizophrenic patients, on lipid peroxidation in plasma and blood platelets at in vitro studies. Psychiatr Psychol Klin 4:215-223.
11. Dietrich-Muszalska A. 2005. The impact of different concentrations of clozapine on changes of lipid peroxidation in human plasma- in vitro studies. Psychiatr Psychol Klin 1:18-25.
12. Dietrich-Muszalska A, Olas B. 2007a. Isoprostanes as indicators of oxidative stress in schizophrenia. World J Biol Psychiatry 11:1-7.
13. Dietrich-Muszalska A, Olas B. 2007b. The changes of aggregability of blood platelets in schizophrenia. World J Biol Psychiatry 14:1-6.
14. Dietrich-Muszalska A, Rabe-Jablonska J, Zgirski A. 2004. The effects of olanzapine (Zolafren) on lipid peroxidation in human blood platelets and plasma: in vitro studies. Psychiatr Psychol Klin 4:13-19.
15. Dietrich-Muszalska A, Olas B, Rabe-Jablonska J. 2005. Oxidative stress in blood platelets from schizophrenic patients. Platelets 16:386-391. (Pubitemid 41564335)
16. Dinan TG. 1987. Neuroleptic effects on platelet aggregation: a study in normal volunteers and schizophrenics. Psychol Med 17:875-881. (Pubitemid 17166558)
17. Doolittle RF, Watt KWK, Cottrell BA, Strong DD, Riley M. 1979. The amino acid sequence of the alpha-chain of human fibrinogen. Nature 280:464-468. (Pubitemid 9234556)
18. Eerdekens M, Hove IV, Remmerie B, Mannaert E. 2004. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res 70:91-100. (Pubitemid 38916632)
19. Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Mö ller HJ. 2005. WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry 6:132-191.
20. Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Mö ller HJ. 2006. WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World J Biol Psychiatry 7:5-40. (Pubitemid 43878525)
21. Farrel DH, Thiagarajan P, Chung DW, Davie EW. 1992. Role of fibrinogen and chain sites in platelet aggregation. Proc Natl Acad Sci USA 89:10729-10732.
22. Feinbloom D, Bauer KA. 2005. Assessment of hemostatic risk factors in predicting arterial thrombotic events. Arterioscler Thromb Vasc Biol 25:2043-2053.
23. Frolich KW, Aarbakke GM, Holmsen H. 1992. Chlorpromazine increases the turnover of metabolically active phosphoinositides and elevates the steady state level of phosphatidylinositol-4-phosphate in human platelets. Biochem Pharmacol 44:2013-2020.
24. Gachet C, Cazenave JP. 2002. Platelet receptors: ADP. In: Gresele P, Page CP, Fuster V, Vermylen J, editors. Platelets in thrombotic and non-thrombotic disorders. Cambridge: Cambridge University Press. pp 127-139.
25. Haslam RJ. 1973. Interaction of the pharmacological receptors of blood platelets with adenylate cyclase. Ser Haematol 6: 333-350.
26. Ishigooka J, Shizu Y, Wakatabe H, Tanaka K, Miura S. 1985. Different effects of centrally acting drugs on rabbit platelet aggregation; with special reference to selective inhibitory effects of antipsychotic and antidepressants. Biol Psychiatry 20: 866-873.
27. Jeding I, Evans PJ, Akanmu D, Dexter D, Spencer JD, Arunoma OI, et al. 1995. Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs. Biochem Pharmacol 49:359-365.
28. Kamath S, Blann AD, Lip GYH. 2001. Platelet activation: assessment and quantification. Eur Heart J 22:1561-1571.
29. Laasvatn KO, Holmsen H. 1999. Chlorpromazine and human platelet glycerolipid metabolism: precursor specificity and significance of drug-platelet interaction time. Biochem Pharmacol 44:1113-1123.
30. Lohr JB, Kuczenski R, Bracha HS, Moir M, Jeste DV. 1990. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol Psychiatry 15:535-539.
31. McNicol A. 1995. Platelet preparation and estimation of functional responses. In: Watson SP, Authi KS, editors. Platelets. A practical approach. Oxford, New York, Tokyo: Oxford University Press. pp 1-6.
32. McNicol A, Israels SJ. 2003. Platelets and anti-platelet therapy. J Pharmacol Sci 93:381-396.
33. Meltzer HY. 1995. Role of serotonin in the action of atypical antipsychotic drugs. Clin Neurosci 3:64-75.
34. Michelson AD. 2003. How platelets work: platelet function and dysfunction. J Thromb 16:7-12.
35. Mö ller HJ. 2004. Novel antipsychotics in the long-term treatment of schizophrenia. World J Biol Psychiatry 5:9-19.
36. Numata S, Kato O, Misawa H, Tokuda H, Kasahara T, Ohmori T. 2005. Left atrial thrombosis associated with antipsychotic drugs. Prog Neuro- Psychopharmacol Biol Psychiatry 29:153-155.
37. Nowak P, Wachowicz B. 2002. Peroxynitrite-mediated modification of fibrinogen affects platelet aggregation and adhesion. Platelets 13:293-299.
38. Offermanns G. 2006. Activation of platelet function through G-protein-coupled receptors. Circ Res 99:1293-1304.
39. Peet M, Laugharne J, Rangarajan N, Reynolds GP. 1993. Tardive dyskinesia, lipid peorxidation, and sustained amelioration with vitamin E treatment. Int Clin Psychophamacol 8:151-153.
40. Plein H, Berk M. 2001. The platelet as a peripheral marker in psychiatric illness. Hum Psychopharmacol Clin Exp 16: 229-236.
41. Ruschena D, Mullen PE, Burgess P, Codner SM, Barry-Walsh J, Drummer OH, et al. 1998. Sudden death in psychiatric patients. Br J Psychiatry 172:331-336.
42. Sheehan DV, Lecrubier Y, Sheenhan KH, Amorim P, Janavs J, Weiller E, et al. 1998. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20):22-33.
43. Taylor D, Paton C, Kerwin R. 2003. The South London and Maudsley NHS Trust. Prescribing guidelines. 7th ed. London, New York: Martin Dunitz, Taylor & Francis Group.
44. Thomassen R, Vandenbroucke JP, Rosendaal FR. 2001. Antipsychotic medication and venous thrombosis. Br J Psychiatry 179:63-66.
45. The United States Pharmacopoeia Drug Information 2000. Drug Information for the Health Care Professional. Vol I. 20th ed. Greenwood Village, CO: Thomson Micromedex.
46. von Kanel R. 2004. Platelet hyperactivity in clinical depression and the beneficial effect of antidepressant drug treatment: how strong is the evidence? Acta Psychiatr Scand 110:163-177.
47. Wallaschofski H, Donne M, Eigenthaler M, Hentschel R, Faber R, Stepan H, et al. 2001. PRL as a novel potent cofactor for platelet aggregation. J Clin Endocrinol Metab 86:5912-5919.
48. Wallaschofski H, Eigenthaler M, Kiefer M, Donne M, Betina H, Gertz H, et al. 2003. Hyperprolactinemia in patients on antipsychotic drags causes ADP-stimulated platelet activation that might explain the increased risk for venous thromboembolism: pilot study. J Clin Psychopharmacol 23:479-483.
49. Walsh MT, Ryan M, Hillmann A, Condren R, Kenny D, Dinan T, et al. 2002. Elevated expression of integrin aIIbbIIIa in drugnaive, first episode schizophrenic patients. Biol Psychiatry 52:874-879.
50. Wu K. 1996. Platelet activation mechanisms and marker in arterial thrombosis. J Intern Med 239:17-34.
51. Yang TY, Chung KJ, Huang TL, Te-Kung CH. 2004. Massive pulmonary embolism in a young patient on clozapine therapy. J Emergency Med 27:27-29.
52. Yao JK, Yasaei P, van Kammen DP. 1992. Increased turnover of platelet phosphatidylinositol in schizophrenia. Prostaglandins Leukotrienes Essent Fatty Acids 46:39-46.
53. Yao JK, van Kammen DP, Gurklis JA, Peters JL. 1994. Platelet aggregation and dense granule secretion in schizophrenia. Psychiatry Res 54:13-24.
54. Yao JK, van Kammen DP, Moss HB, Sokulski DE. 1996. Decreased serotonic responsivity in platelet of drug-free patients with schizophrenia. Psychiatr Res 63:123-132.
55. Yao JK, Magan S, Sonel AF, Gurklis JA, Sanders R, Reddy RD. 2004. Effects of omega-3 fatty acid on platelet serotonin responsivity in patients with schizophrenia. Prostaglandins Leukotriens Essent Fatty Acids 71:171-176.
56. Zornberg GL, Jick H. 2000. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet 356:1219-1223